225 related articles for article (PubMed ID: 25519488)
21. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
[TBL] [Abstract][Full Text] [Related]
22. Point-of-care companion diagnostic tests for personalizing psychiatric medications: fulfilling an unmet clinical need.
Modak AS
J Breath Res; 2017 Dec; 12(1):017101. PubMed ID: 28920579
[TBL] [Abstract][Full Text] [Related]
23. Effect of CYP2D6, 2C19, and 3A4 Phenoconversion in Drug-Related Deaths.
Aly SM; Hennart B; Gaulier JM; Allorge D
Toxics; 2024 Mar; 12(4):. PubMed ID: 38668482
[TBL] [Abstract][Full Text] [Related]
24. Phenoconversion of CYP2C9 in epilepsy limits the predictive value of CYP2C9 genotype in optimizing valproate therapy.
Tóth K; Bűdi T; Kiss Á; Temesvári M; Háfra E; Nagy A; Szever Z; Monostory K
Per Med; 2015 Jun; 12(3):199-207. PubMed ID: 29771647
[TBL] [Abstract][Full Text] [Related]
25. Bench to bedside: Pharmacogenomics, adverse drug interactions, and the cytochrome P450 system.
Sikka R; Magauran B; Ulrich A; Shannon M
Acad Emerg Med; 2005 Dec; 12(12):1227-35. PubMed ID: 16282513
[TBL] [Abstract][Full Text] [Related]
26. HepaRG cells as human-relevant in vitro model to study the effects of inflammatory stimuli on cytochrome P450 isoenzymes.
Rubin K; Janefeldt A; Andersson L; Berke Z; Grime K; Andersson TB
Drug Metab Dispos; 2015 Jan; 43(1):119-25. PubMed ID: 25371393
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenomic protocols in CNS disorders and dementia.
Cacabelos R
Neurodegener Dis; 2010; 7(1-3):167-9. PubMed ID: 20197699
[TBL] [Abstract][Full Text] [Related]
28. Quantifying the Impact of Phenoconversion on Medications With Actionable Pharmacogenomic Guideline Recommendations in an Acute Aged Persons Mental Health Setting.
Mostafa S; Polasek TM; Sheffield LJ; Huppert D; Kirkpatrick CMJ
Front Psychiatry; 2021; 12():724170. PubMed ID: 34489765
[No Abstract] [Full Text] [Related]
29. Cytochrome p450 part 2: what nurses need to know about the cytochrome p450 family systems.
Krau SD
Nurs Clin North Am; 2013 Dec; 48(4):681-96. PubMed ID: 24295195
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of phenoconversion phenomenon in obese patients: the effects of bariatric surgery on the CYP450 activity "a protocol for a case-control pharmacokinetic study".
Ghasim H; Rouini M; Gholami K; Larti F; Safari S; Ardakani YH
J Diabetes Metab Disord; 2021 Dec; 20(2):2085-2092. PubMed ID: 34900844
[TBL] [Abstract][Full Text] [Related]
32. Cytochrome P450 enzymes and genotype-guided drug therapy.
Roederer MW
Curr Opin Mol Ther; 2009 Dec; 11(6):632-40. PubMed ID: 20072940
[TBL] [Abstract][Full Text] [Related]
33. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
Lynch T; Price A
Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
[TBL] [Abstract][Full Text] [Related]
34. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
[TBL] [Abstract][Full Text] [Related]
35. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
36. In vitro evaluation of the interaction potential of irosustat with drug-metabolizing enzymes.
Ventura V; Solà J; Peraire C; Brée F; Obach R
Drug Metab Dispos; 2012 Jul; 40(7):1268-78. PubMed ID: 22451700
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibodies and multifunctional cytochrome P450: drug metabolism as paradigm.
Gelboin HV; Krausz K
J Clin Pharmacol; 2006 Mar; 46(3):353-72. PubMed ID: 16490812
[TBL] [Abstract][Full Text] [Related]
38. CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes.
Davies BJ; Coller JK; Somogyi AA; Milne RW; Sallustio BC
Drug Metab Dispos; 2007 Jan; 35(1):128-38. PubMed ID: 17050648
[TBL] [Abstract][Full Text] [Related]
39. Risk assessment of accidental nortriptyline poisoning: the importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator.
Jornil J; Jensen KG; Larsen F; Linnet K
Eur J Pharm Sci; 2011 Oct; 44(3):265-72. PubMed ID: 21854846
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of liver drug-metabolizing enzymes in a murine model of chronic renal failure.
Dani M; Boisvert C; Michaud J; Naud J; Lefrançois S; Leblond FA; Pichette V
Drug Metab Dispos; 2010 Mar; 38(3):357-60. PubMed ID: 20007296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
